<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2007-4085</journal-id>
<journal-title><![CDATA[Revista mexicana de urología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. urol.]]></abbrev-journal-title>
<issn>2007-4085</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Urología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2007-40852017000600453</article-id>
<article-id pub-id-type="doi">10.24245/revmexurol.v77i6.1179</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Aplicación intravesical de toxina botulínica y su repercusión en la calidad de vida de pacientes con lesión medular y vejiga neurogénica. Experiencia institucional]]></article-title>
<article-title xml:lang="en"><![CDATA[Impact of intravesical application of botulinum toxin on quality of life of patients with spinal cord injury and neurogenic bladder: Experience at a national rehabilitation center]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Durán-Ortiz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Herrera]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez-Hernández]]></surname>
<given-names><![CDATA[BO]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez-Zavala]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[León]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Rehabilitación Departamento de Urología ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Nacional de Rehabilitación Departamento de Rehabilitación Neurológica ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<volume>77</volume>
<numero>6</numero>
<fpage>453</fpage>
<lpage>463</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2007-40852017000600453&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2007-40852017000600453&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2007-40852017000600453&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  ANTECEDENTES:  La vejiga neurogénica es un padecimiento común en pacientes con lesión medular, que provoca efectos devastadores y gran repercusión en la calidad de vida.  OBJETIVO:  Determinar la calidad de vida en pacientes con lesión medular y vejiga neurogénica después de la aplicación intravesical de toxina botulínica.  MATERIALES Y MÉTODOS:  Estudio descriptivo y prospectivo efectuado en pacientes con lesión medular y vejiga neurogénica de alta presión y disinergia vesicoesfinteriana comprobada mediante estudio urodinámico. Se realizó una encuesta antes de la aplicación, un mes y tres meses después de la administración de la toxina botulínica. Se evaluaron aspectos sociales, laborales, psicológicos y funcionales. Se efectuó el estudio urodinámico luego de 3 meses de la aplicación de la toxina.  RESULTADOS:  Se registraron 16 pacientes con lesión medular y vejiga neurogénica; los cambios en los parámetros del cuestionario que evaluaron la calidad de vida al mes y tres meses posaplicación, en comparación con la valoración preaplicación fueron estadísticamente significativos. En todos los pacientes se observó un aumento en la capacidad vesical (20-80 mL). Esta variable no se relacionó con la edad, sexo, ni tiempo de evolución de la lesión. Se observó que a menor capacidad vesical antes de la aplicación de la toxina, mayor aumento en la capacidad vesical en el estudio urodinámico de control.  CONCLUSIONES:  La aplicación intravesical de toxina botulínica mejora la calidad de vida de pacientes con lesión medular y vejiga neurogénica; además, disminuye las complicaciones urológicas crónicas y representa un procedimiento de baja morbilidad y mortalidad.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  BACKGROUND:  Neurogenic bladder is a common disorder in patients with spinal cord injury. Its effects are devastating, profoundly impacting the quality of life of those patients.  AIM:  To determine the effect of botulinum toxin application on the quality of life of patients with spinal cord injury and neurogenic bladder.  MATERIALS AND METHODS:  A descriptive, prospective analysis was conducted on patients with spinal cord injury, high pressure neurogenic bladder, and vesicosphincter dyssynergia corroborated through urodynamic study. A questionnaire was applied before botulinum toxin application, and again, one and three months after application, covering social, occupational, psychologic, and functional aspects. Urodynamic study was performed at a minimum of 3 months after botulinum toxin application.  RESULTS:  Sixteen patients with spinal cord injury and neurogenic bladder were enrolled in the study. There were statistically significant changes in the questionnaire parameters evaluating quality of life at one and three months after the procedure, compared with the preapplication results. All patients had an increase in bladder capacity (20-80 mL), regardless of patient age, sex, or time with spinal cord injury. Patients with a lower bladder capacity before botulinum toxin application had a higher increase in bladder capacity in the control urodynamic study.  CONCLUSIONS:  Intravesical botulinum toxin application improves the quality of life in patients with spinal cord injury and neurogenic bladder, reducing chronic urologic complications, in addition to being a procedure with low morbidity and mortality.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[lesión medular]]></kwd>
<kwd lng="es"><![CDATA[vejiga neurogénica]]></kwd>
<kwd lng="es"><![CDATA[disinergia vesicoesfinteriana]]></kwd>
<kwd lng="es"><![CDATA[toxina botulínica]]></kwd>
<kwd lng="en"><![CDATA[Spinal cord injury]]></kwd>
<kwd lng="en"><![CDATA[Neurogenic bladder]]></kwd>
<kwd lng="en"><![CDATA[Vesicosphincter dyssynergia]]></kwd>
<kwd lng="en"><![CDATA[Botulinum toxin]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Danforth]]></surname>
<given-names><![CDATA[TL]]></given-names>
</name>
<name>
<surname><![CDATA[Ginsberg]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neurogenic lower urinary tract dysfunction]]></article-title>
<source><![CDATA[Urol Clin N Am]]></source>
<year>2014</year>
<volume>41</volume>
<page-range>445-52</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jeong]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
<name>
<surname><![CDATA[Oh]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Spinal cord/brain injury and the neurogenic bladder]]></article-title>
<source><![CDATA[Urol Clin N Am]]></source>
<year>2010</year>
<volume>37</volume>
<page-range>537-46</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Middleton]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ramakrishnan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Cameron]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<source><![CDATA[Management of the neurogenic bladder for adults with spinal cord injuries]]></source>
<year>2014</year>
<edition>3</edition>
<publisher-loc><![CDATA[Sydney ]]></publisher-loc>
<publisher-name><![CDATA[NSW Agency for Clinical Innovation]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jonas]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Castro-Díaz]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bemelmans]]></surname>
<given-names><![CDATA[BLH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neurogenic voiding dysfunctions]]></article-title>
<source><![CDATA[Eur Urol]]></source>
<year>2003</year>
<volume>44</volume>
<page-range>I-XV</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gormley]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Urologic Complications of the neurogenic bladder]]></article-title>
<source><![CDATA[Urol Clin N Am]]></source>
<year>2010</year>
<volume>37</volume>
<page-range>601-7</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McGuire]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Urodynamics of the neurogenic bladder]]></article-title>
<source><![CDATA[Urol Clin N Am]]></source>
<year>2010</year>
<volume>37</volume>
<page-range>507-16</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Patterson]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Chapple]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: A critical analysis of results]]></article-title>
<source><![CDATA[Eur Urol]]></source>
<year>2006</year>
<volume>50</volume>
<page-range>684-710</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cameron]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacologic therapy for the neurogenic bladder]]></article-title>
<source><![CDATA[Urol Clin N Am]]></source>
<year>2010</year>
<volume>37</volume>
<page-range>495-506</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Apostolidis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dasgupta]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Denys]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: A European Consensus Report]]></article-title>
<source><![CDATA[Eur Urol]]></source>
<year>2009</year>
<volume>55</volume>
<page-range>100-19</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schurh]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Schulte-Baukloh]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Botulinum toxin in the treatment of neurogenic bladder in adults and children]]></article-title>
<source><![CDATA[Eur Urol]]></source>
<year>2006</year>
<volume>5</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>679-84</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Neel]]></surname>
<given-names><![CDATA[KF]]></given-names>
</name>
<name>
<surname><![CDATA[Soliman]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Salem]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Botulinum a toxin: solo treatment for neuropathic noncompliant bladder]]></article-title>
<source><![CDATA[J Urol]]></source>
<year>2007</year>
<volume>178</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2593-8</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guzmán]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Honeck]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Weiss]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inyección de toxina botulínica en disfunción vesical neurogénica y no neurogénica]]></article-title>
<source><![CDATA[Arch Esp Urol]]></source>
<year>2005</year>
<volume>58</volume>
<page-range>651-5</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kuo]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recovery of detrusor function after urethral botulinum a toxin injection in patients with idiopathic low detrusor contractility and voiding dysfunction]]></article-title>
<source><![CDATA[Urology]]></source>
<year>2007</year>
<volume>69</volume>
<page-range>57-62</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duthie]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Vincent]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Herbinson]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Botulinum toxin injections for adults with overactive bladder syndrome]]></article-title>
<source><![CDATA[The Cochrane Database Syst Rev]]></source>
<year>2011</year>
<volume>12</volume>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Karsenty]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Denys]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Amarenco]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Botulinum toxin a (botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review]]></article-title>
<source><![CDATA[Eur Urol]]></source>
<year>2008</year>
<volume>53</volume>
<page-range>275-87</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liao]]></surname>
<given-names><![CDATA[YM]]></given-names>
</name>
<name>
<surname><![CDATA[Kuo]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Causes of failed urethral botulinum toxin a treatment for emptying failure]]></article-title>
<source><![CDATA[Urology]]></source>
<year>2007</year>
<volume>70</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>763-6</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
